What is Immunic Therapeutics's official website?

Immunic Therapeutics's website is https://imux.com

How many employees are working in Immunic Therapeutics right now?

Immunic Therapeutics has 87 employees.

What is Immunic Therapeutics's industry?

Immunic Therapeutics's industry is Biotechnology Research

Who are Immunic Therapeutics's top competitors?

Immunic Therapeutics's top competitors are , , , , , ,

Immunic Therapeutics company information, Employees & Contact Information

Explore related pages

Immunic Therapeutics email format Immunic Therapeutics management contacts

Related company profiles:

Immunic (Nasdaq: IMUX) is a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases. Privacy Policy: https://imux.com/privacy-policy/

Employees: 87
Founded: -
Address: 1200 Avenue Of The Americas, Suite 200,germany
Phone: 4989208047700
Email: in****@****unic.de
Industry: Biotechnology Research
NAICS: Research and Development in Biotechnology (except Nanobiotechnology)
Website: https://imux.com
Keywords: Manager jobs.
HQ: New York City, New York
Competitors: Royalty Pharma, Tourmaline Bio, ScieGen Pharmaceuticals Inc, Gilgamesh Pharmaceuticals, Anavex Life Sciences, Dianthus Therapeutics, Inc., Envisagenics, Lexeo Therapeutics, Nuvation Bio, BioSpherix, LLC.

Immunic Therapeutics Questions

News

Immunic to Participate in Scientific and Investor Conferences in October - PR Newswire

Immunic to Participate in Scientific and Investor Conferences in October PR Newswire

Breakthrough Celiac Disease Treatment: Immunic's IMU-856 Shows Positive Effects in Phase 1 Trial Presentation - Stock Titan

Breakthrough Celiac Disease Treatment: Immunic's IMU-856 Shows Positive Effects in Phase 1 Trial Presentation Stock Titan

Immunic Presented Key Vidofludimus Calcium Data at the 41st Congress of ECTRIMS, Highlighting Its Potential in Multiple Sclerosis - PR Newswire

Immunic Presented Key Vidofludimus Calcium Data at the 41st Congress of ECTRIMS, Highlighting Its Potential in Multiple Sclerosis PR Newswire

Immunic, Inc. Announces Pricing of Oversubscribed $65 Million Underwritten Public Offering - Stocktwits

Immunic, Inc. Announces Pricing of Oversubscribed $65 Million Underwritten Public Offering Stocktwits

Key Multiple Sclerosis Drug Data: Immunic's Vidofludimus Phase 2 Results Coming at ECTRIMS Congress - Stock Titan

Key Multiple Sclerosis Drug Data: Immunic's Vidofludimus Phase 2 Results Coming at ECTRIMS Congress Stock Titan

Immunic, Inc. Reports Second Quarter 2025 Financial Results and Provides Corporate Update - PR Newswire

Immunic, Inc. Reports Second Quarter 2025 Financial Results and Provides Corporate Update PR Newswire

Immunic, Inc. Announces Proposed Public Offering - Stocktwits

Immunic, Inc. Announces Proposed Public Offering Stocktwits

Immunic Secures Patent for MS Drug Vidofludimus Through 2041 | IMUX Stock News - Stock Titan

Immunic Secures Patent for MS Drug Vidofludimus Through 2041 | IMUX Stock News Stock Titan

Immunic, Inc. Announces Pricing of $5.1 Million Registered Direct Offering, Led by Aberdeen Investments - PR Newswire

Immunic, Inc. Announces Pricing of $5.1 Million Registered Direct Offering, Led by Aberdeen Investments PR Newswire

Clinical Trial Results: New MS Drug Prevents Disability in 92% of Patients After 3 Years - Stock Titan

Clinical Trial Results: New MS Drug Prevents Disability in 92% of Patients After 3 Years Stock Titan

Immunic Highlights 2024 Accomplishments and Upcoming Milestones - PR Newswire

Immunic Highlights 2024 Accomplishments and Upcoming Milestones PR Newswire

Immunic Secures $240M Funding as Multiple Sclerosis Drug Trials Show Promise in Phase 3 - Stock Titan

Immunic Secures $240M Funding as Multiple Sclerosis Drug Trials Show Promise in Phase 3 Stock Titan

Immunic, Inc. Reports Third Quarter 2024 Financial Results and Provides Corporate Update - PR Newswire

Immunic, Inc. Reports Third Quarter 2024 Financial Results and Provides Corporate Update PR Newswire

Immunic Announces Publication of Data From Phase 1/1b Clinical Trial of IMU-856 in the Peer Reviewed Journal, The Lancet Gastroenterology & Hepatology - PR Newswire

Immunic Announces Publication of Data From Phase 1/1b Clinical Trial of IMU-856 in the Peer Reviewed Journal, The Lancet Gastroenterology & Hepatology PR Newswire

Immunic, Inc. Announces Closing of Oversubscribed $65 Million Underwritten Public Offering - PR Newswire

Immunic, Inc. Announces Closing of Oversubscribed $65 Million Underwritten Public Offering PR Newswire

Immunic, Inc. Announces Proposed Public Offering - PR Newswire

Immunic, Inc. Announces Proposed Public Offering PR Newswire

Immunic to Participate in Investor and Scientific Conferences in September - PR Newswire

Immunic to Participate in Investor and Scientific Conferences in September PR Newswire

Immunic Appoints Jason Tardio as Chief Operating Officer and President - PR Newswire

Immunic Appoints Jason Tardio as Chief Operating Officer and President PR Newswire

Immunic to Participate in Investor, Scientific and Industry Conferences in June - PR Newswire

Immunic to Participate in Investor, Scientific and Industry Conferences in June PR Newswire

Immunic Announces Completion of Enrollment for Both Phase 3 ENSURE Trials in Relapsing MS and Presents Additional Data Underlining Positive Outcome of Phase 2 CALLIPER Trial in Progressive MS - PR Newswire

Immunic Announces Completion of Enrollment for Both Phase 3 ENSURE Trials in Relapsing MS and Presents Additional Data Underlining Positive Outcome of Phase 2 CALLIPER Trial in Progressive MS PR Newswire

Immunic Announces Vidofludimus Calcium Reduced Risk of Disability Worsening by 30% in Primary Progressive Multiple Sclerosis Patients from Phase 2 CALLIPER Trial - PR Newswire

Immunic Announces Vidofludimus Calcium Reduced Risk of Disability Worsening by 30% in Primary Progressive Multiple Sclerosis Patients from Phase 2 CALLIPER Trial PR Newswire

Immunic, Inc. Announces Private Placement of up to $240 Million - PR Newswire

Immunic, Inc. Announces Private Placement of up to $240 Million PR Newswire

Immunic Announces Positive Outcome of Interim Analysis of Phase 3 ENSURE Program of Vidofludimus Calcium in Relapsing Multiple Sclerosis - PR Newswire

Immunic Announces Positive Outcome of Interim Analysis of Phase 3 ENSURE Program of Vidofludimus Calcium in Relapsing Multiple Sclerosis PR Newswire

Immunic, Inc. to Announce Financial Results for the Second Quarter Ended June 30, 2024, and Provide Corporate Update - Stock Titan

Immunic, Inc. to Announce Financial Results for the Second Quarter Ended June 30, 2024, and Provide Corporate Update Stock Titan

Immunic Appoints Jason Tardio as Chief Operating Officer and President - citybiz

Immunic Appoints Jason Tardio as Chief Operating Officer and President citybiz

Is treatment for multiple sclerosis about to change fundamentally? - Fierce Pharma

Is treatment for multiple sclerosis about to change fundamentally? Fierce Pharma

Immunic Appoints Richard Rudick, M.D. to Board - citybiz

Immunic Appoints Richard Rudick, M.D. to Board citybiz

Immunic Appoints Maria Törnsén to Board - citybiz

Immunic Appoints Maria Törnsén to Board citybiz

Immunic Promotes Glenn Whaley, CPA to CFO - citybiz

Immunic Promotes Glenn Whaley, CPA to CFO citybiz

Companies like Immunic Therapeutics

Top Immunic Therapeutics Employees

Andreas Muehler

n/a

N/a

View
Vicky Weichsler

Accomplished Cross-Functional Drug…

Eurasburg, Bavaria, Germany, Germany

View
Duane Nash MD JD MBA

n/a

San Diego, California, United States, United States

View

4
vitaltherapies.com, oba.co.uk, dpw.com, immunic-therapeutics.com
Jacques Arend

n/a

Leiden, South Holland, Netherlands, Netherlands

View

3
hotmail.com, am-pharma.com, am-pharma.com

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles

Get direct phone numbers & mobile contacts

Access company data & employee information

Works directly on LinkedIn - no copy/paste needed

Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant

Learn More

How It Works

Get a Free Account

Search the #1 Contact Database

Get contact details of over 750M+ profiles across 60M companies – all with industry-leading accuracy. Sales Navigator and Recruiter users, try out our Email Finder Extension.

Use our AI-Powered Email Finder

Find business and personal emails and mobile phone numbers with exclusive coverage across niche job titles, industries, and more for unparalleled targeting. Also available via our Contact Data API.

Have a look at Aeroleads Data

Browse our Data

Company Search

a b c d e f g h i j k l m n o p q r s t u v w x y z

Profile Search

a b c d e f g h i j k l m n o p q r s t u v w x y z

List Search

a b c d e f g h i j k l m n o p q r s t u v w x y z

Immunic Therapeutics company information, Employees & Contact Information

Explore related pages

Company Details

Immunic Therapeutics Questions

What is Immunic Therapeutics's helpline number?

What is Immunic Therapeutics's official website?

What is Immunic Therapeutics's LinkedIn profile?

How many employees are working in Immunic Therapeutics right now?

What is Immunic Therapeutics's industry?

What are Immunic Therapeutics's top competitors?

What is Immunic Therapeutics's support email address?

What are Immunic Therapeutics's categories?

When was Immunic Therapeutics founded?

News

Immunic to Participate in Scientific and Investor Conferences in October - PR Newswire

Breakthrough Celiac Disease Treatment: Immunic's IMU-856 Shows Positive Effects in Phase 1 Trial Presentation - Stock Titan

Immunic Presented Key Vidofludimus Calcium Data at the 41st Congress of ECTRIMS, Highlighting Its Potential in Multiple Sclerosis - PR Newswire

Immunic, Inc. Announces Pricing of Oversubscribed $65 Million Underwritten Public Offering - Stocktwits

Key Multiple Sclerosis Drug Data: Immunic's Vidofludimus Phase 2 Results Coming at ECTRIMS Congress - Stock Titan

Immunic, Inc. Reports Second Quarter 2025 Financial Results and Provides Corporate Update - PR Newswire

Immunic, Inc. Announces Proposed Public Offering - Stocktwits

Immunic Secures Patent for MS Drug Vidofludimus Through 2041 | IMUX Stock News - Stock Titan

Immunic, Inc. Announces Pricing of $5.1 Million Registered Direct Offering, Led by Aberdeen Investments - PR Newswire

Clinical Trial Results: New MS Drug Prevents Disability in 92% of Patients After 3 Years - Stock Titan

Immunic Highlights 2024 Accomplishments and Upcoming Milestones - PR Newswire

Immunic Secures $240M Funding as Multiple Sclerosis Drug Trials Show Promise in Phase 3 - Stock Titan

Immunic, Inc. Reports Third Quarter 2024 Financial Results and Provides Corporate Update - PR Newswire

Immunic Announces Publication of Data From Phase 1/1b Clinical Trial of IMU-856 in the Peer Reviewed Journal, The Lancet Gastroenterology & Hepatology - PR Newswire

Immunic, Inc. Announces Closing of Oversubscribed $65 Million Underwritten Public Offering - PR Newswire

Immunic, Inc. Announces Proposed Public Offering - PR Newswire

Immunic to Participate in Investor and Scientific Conferences in September - PR Newswire

Immunic Appoints Jason Tardio as Chief Operating Officer and President - PR Newswire

Immunic to Participate in Investor, Scientific and Industry Conferences in June - PR Newswire

Immunic Announces Completion of Enrollment for Both Phase 3 ENSURE Trials in Relapsing MS and Presents Additional Data Underlining Positive Outcome of Phase 2 CALLIPER Trial in Progressive MS - PR Newswire

Immunic Announces Vidofludimus Calcium Reduced Risk of Disability Worsening by 30% in Primary Progressive Multiple Sclerosis Patients from Phase 2 CALLIPER Trial - PR Newswire

Immunic, Inc. Announces Private Placement of up to $240 Million - PR Newswire

Immunic Announces Positive Outcome of Interim Analysis of Phase 3 ENSURE Program of Vidofludimus Calcium in Relapsing Multiple Sclerosis - PR Newswire

Immunic, Inc. to Announce Financial Results for the Second Quarter Ended June 30, 2024, and Provide Corporate Update - Stock Titan

Immunic Appoints Jason Tardio as Chief Operating Officer and President - citybiz

Is treatment for multiple sclerosis about to change fundamentally? - Fierce Pharma

Immunic Appoints Richard Rudick, M.D. to Board - citybiz

Immunic Appoints Maria Törnsén to Board - citybiz

Immunic Promotes Glenn Whaley, CPA to CFO - citybiz

Companies like Immunic Therapeutics

Tourmaline Bio

Lexeo Therapeutics

Dianthus Therapeutic...

Sciegen Pharmaceutic...

Gilgamesh Pharmaceut...

Nuvation Bio

Royalty Pharma

Anavex Life Sciences

Envisagenics

Biospherix, Llc

Top Immunic Therapeutics Employees

Andreas Muehler

n/a

Vicky Weichsler

Accomplished Cross-Functional Drug…

Duane Nash MD JD MBA

n/a

Jacques Arend

n/a

Free Chrome Extension

Aero Online

Select data to include:

How It Works

Get a Free Account

Search the #1 Contact Database

Use our AI-Powered Email Finder

Have a look at Aeroleads Data